Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:12:21.381Z.
Calculation as of: 2026-10-06T16:12:21.381Z.
Quote observation: 2026-10-06T16:10:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 87a3ef4e55b06d985fb23947e4d9ae6563d80488a3a61227015f8099389db825
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$381940.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$816286.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$845829.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$858810.00
Price/FCF Ratio
N/A
TTM Avg
13238.57
3Y Avg
13238.57
5Y Avg
13238.57
Market Cap
$859931.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HCW Biologics Inc. (HCWB) | $563178.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $669300.00 | N/A | 0.46 | 0.46 | 0.46 |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | N/A | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $809925.00 | N/A | 0.22 | 0.19 | 1.45 |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $816286.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $845829.00 | N/A | N/A | N/A | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $858810.00 | N/A | 13238.57 | 13238.57 | 13238.57 |
| Bone Biologics Corporation (BBLG)vs › | $859931.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $873967.00 | N/A | N/A | N/A | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $94810.00 | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
